Literature DB >> 20848438

Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition.

Uttam K Sinha1, Victor J Schorn, Christian Hochstim, Steven B Chinn, Sutao Zhu, Rizwan Masood.   

Abstract

BACKGROUND: Sphingosine kinase 1 (SphK1) is an important regulator of apoptosis, survival, and proliferation in cancer cells. SphK1 expression in head and neck squamous cell cancer (HNSCC) cell lines and tumor tissue was assessed, and the efficacy of SphK1 knockdown in increasing tumor radiosensitivity was evaluated in vitro and in vivo.
METHODS: Expression of SphK1 was determined by immunohistochemistry, Western blot, and real-time polymerase chain reaction (RT-PCR) in 34 prospectively collected HNSCC tumor samples. HNSCC cell lines squamous cell carcinoma (SCC)-15 and SCC-25 were treated with SphK1 inhibitor SKI-II and siRNA targeting SphK1 with and without radiation, and the cell viability was assessed. SCC-15 cells with and without transfection of SphK1 siRNA were then injected into athymic nude mice to develop tumor xenografts, and these 2 groups were further divided into 1 group that received radiation and 1 group that did not. Tumor size was measured over 18 days, when the animals were killed and the tumors were evaluated by immunohistochemistry.
RESULTS: SphK1 is found in both HNSCC cell lines and human tumor samples, with higher expression correlated with advanced tumor stage, nodal involvement, and recurrence. In vitro, both SCC-15 and SCC-25 were found to be radioresistant; however, they were sensitized by administration of SKI-II and transfection with siRNA targeting SphK1. In vivo, SphK1-siRNA transfected xenografts were decreased in size compared with both nonradiated control and radiated control mice, whereas mice with both SphK1-siRNA and radiation treatment showed a synergistic reduction in tumor volume. Histopathologic analysis demonstrated a decreased proliferative state in SphK1-siRNA transfected tumors.
CONCLUSION: SphK1 is upregulated in HNSCC, and inhibition of SphK1 sensitizes HNSCC to radiation-induced cytotoxicity.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20848438     DOI: 10.1002/hed.21418

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  24 in total

Review 1.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

2.  High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.

Authors:  Kai Zhang; Hao Chen; Guizhong Wu; Kangwu Chen; Huilin Yang
Journal:  Med Oncol       Date:  2014-09-27       Impact factor: 3.064

Review 3.  Exploring the link between ceramide and ionizing radiation.

Authors:  Massimo Aureli; Valentina Murdica; Nicoletta Loberto; Maura Samarani; Alessandro Prinetti; Rosaria Bassi; Sandro Sonnino
Journal:  Glycoconj J       Date:  2014-10       Impact factor: 2.916

4.  Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Yuta Kawakita; Satoru Motoyama; Yusuke Sato; Souichi Koyota; Akiyuki Wakita; Jiajia Liu; Hajime Saito; Yoshihiro Minamiya
Journal:  Surg Today       Date:  2017-03-31       Impact factor: 2.549

Review 5.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Authors:  Dmitri Pchejetski; Torsten Böhler; Justin Stebbing; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

Review 6.  Sphingosine kinase 1 in cancer.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 7.  Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy.

Authors:  Christopher R Gault; Lina M Obeid
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-08       Impact factor: 8.250

8.  Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.

Authors:  Francis R LeBlanc; Xin Liu; Jeremy Hengst; Todd Fox; Valerie Calvert; Emanuel F Petricoin; Jong Yun; David J Feith; Thomas P Loughran
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

9.  Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.

Authors:  Jason A Powell; Alexander C Lewis; Wenying Zhu; John Toubia; Melissa R Pitman; Craig T Wallington-Beddoe; Paul A B Moretti; Diana Iarossi; Saumya E Samaraweera; Nik Cummings; Hayley S Ramshaw; Daniel Thomas; Andrew H Wei; Angel F Lopez; Richard J D'Andrea; Ian D Lewis; Stuart M Pitson
Journal:  Blood       Date:  2016-12-12       Impact factor: 22.113

10.  Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins.

Authors:  Lavona Casson; Lauren Howell; Lesley A Mathews; Marc Ferrer; Noel Southall; Rajarshi Guha; Jonathan M Keller; Craig Thomas; Leah J Siskind; Levi J Beverly
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.